• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加纳和肯尼亚抗逆转录病毒药物的注册时间轴。

Registration timelines of antiretroviral medicines in Ghana and Kenya.

机构信息

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

School of Public Health, Faculty of Community Health Sciences, University of the Western Cape, Cape Town, South Africa.

出版信息

AIDS. 2020 Jun 1;34(7):1093-1095. doi: 10.1097/QAD.0000000000002514.

DOI:10.1097/QAD.0000000000002514
PMID:32073445
Abstract

: This study examines registration timelines of antiretroviral medicines (ARVs) in Ghana and Kenya, to assess whether prior reviews by the US Food and Drug Administration Tentative Approval or WHO prequalification (WHO/PQP) affect in-country approval timelines. Data were collected from online and national databases. Median in-country review period in Ghana was 9 months compared with 25 months in Kenya. ARVs with Tentative Approval and WHO/PQP status did not benefit from shorter in-country review periods.

摘要

本研究考察了加纳和肯尼亚抗逆转录病毒药物(ARV)的注册时间线,以评估美国食品和药物管理局(FDA)暂定批准或世界卫生组织(WHO)预认证(WHO/PQP)的预先审查是否会影响国内的审批时间线。数据来自在线数据库和国家数据库。加纳国内审查的中位时间为 9 个月,而肯尼亚为 25 个月。具有暂定批准和 WHO/PQP 地位的 ARV 并没有从较短的国内审查周期中受益。

相似文献

1
Registration timelines of antiretroviral medicines in Ghana and Kenya.加纳和肯尼亚抗逆转录病毒药物的注册时间轴。
AIDS. 2020 Jun 1;34(7):1093-1095. doi: 10.1097/QAD.0000000000002514.
2
HIV antiretroviral medication stock-outs in Ghana: contributors and consequences.加纳的艾滋病毒抗逆转录病毒药物缺货:成因与后果
Afr J AIDS Res. 2017 Sep;16(3):231-239. doi: 10.2989/16085906.2017.1364275.
3
Medicines Control Council and registration backlog of antiretrovirals.药品管理委员会与抗逆转录病毒药物注册积压问题
S Afr Med J. 2007 Mar;97(3):148, 150.
4
The US Food and Drug Administration's tentative approval process and the global fight against HIV.美国食品药品监督管理局的暂定批准程序与全球抗击艾滋病病毒的斗争。
J Int AIDS Soc. 2017 Dec;20(4). doi: 10.1002/jia2.25019.
5
Implementation of HIV care in Western Kenya during corona virus disease 2019 response.在 2019 冠状病毒病应对期间,肯尼亚西部实施艾滋病毒护理。
AIDS. 2020 Jul 1;34(8):F1-F2. doi: 10.1097/QAD.0000000000002576.
6
Simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE): protocol for a randomised evaluation.用于识别符合立即开始抗逆转录病毒治疗条件的HIV患者的简化临床算法(SLATE):一项随机评估方案
BMJ Open. 2017 May 28;7(5):e016340. doi: 10.1136/bmjopen-2017-016340.
7
Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment.美国食品药品监督管理局对抗逆转录病毒药物的注册对全球获得艾滋病治疗的影响。
BMJ Glob Health. 2018 May 17;3(3):e000651. doi: 10.1136/bmjgh-2017-000651. eCollection 2018.
8
An Evaluation of US Food and Drug Administration's Program to Register HIV Drugs for Use in Resource-Constrained Settings.美国食品和药物管理局在资源有限环境下注册艾滋病毒药物使用项目的评估。
JAMA Netw Open. 2019 Nov 1;2(11):e1915787. doi: 10.1001/jamanetworkopen.2019.15787.
9
Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.肯尼亚三个县接受联合抗逆转录病毒疗法的艾滋病毒感染者病毒抑制或反弹的发生率及相关因素。
Int J Infect Dis. 2020 Aug;97:151-158. doi: 10.1016/j.ijid.2020.05.097. Epub 2020 Jun 2.
10
The Effect of Antiretroviral Stock-Outs on Medication Adherence Among Patients Living With HIV in Ghana: A Qualitative Study.抗逆转录病毒药物短缺对加纳艾滋病毒感染者药物依从性的影响:一项定性研究。
J Assoc Nurses AIDS Care. 2018 Mar-Apr;29(2):231-240. doi: 10.1016/j.jana.2017.09.014. Epub 2017 Oct 9.

引用本文的文献

1
Replicative co-infections with human immunodeficiency virus 1 and 2 as well as hepatitis B and C virus in Ghanaian individuals.加纳个体中人类免疫缺陷病毒1型和2型以及乙型和丙型肝炎病毒的复制性合并感染。
Eur J Microbiol Immunol (Bp). 2024 Oct 30;14(4):346-360. doi: 10.1556/1886.2024.00103. Print 2024 Dec 18.